The administration of GSK-J4, a specific inhibitor of JMJD3, effectively mitigated the overexpression of JMJD3 and reversed the hypoexpression of H3K27me3 in NEC mice. This evidence concerns the gene KDM6B and necrotizing enterocolitis.